Dr Anna Sureda, President of the European Society for Blood and Marrow Transplantation (EBMT), shares updates from the joint EBMT-EHA session on GoCART. This is a multi-stakeholder coalition of patient representatives, health care professionals, pharmaceutical companies, regulators, Health Technology Assessment bodies and reimbursement agencies, and medical organisations, collaborating to maximise the potential of cellular therapies manufactured from cells and tissues of hematopoietic origin.
Disclosures: Anna Sureda has received honoraria from Alexion, Amgen, BMS/Celgene, Gilead Kite, Janssen, MSD, Novartis, Roche, Sanofi and Takeda, and consultancy fees from BMS/Celgene, Gilead, Janssen, Novartis, Sanofi and Takeda. She is on the speaker’s bureau for and has received research support from Takeda. Non-profit organizations roles include Presidency of the EBMT and presidency of the GETH-TC.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
